Marina Maglakelidze

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer et al. · Annals of Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.

Marina Maglakelidze, Iurie Bulat, Dinara Ryspayeva et al. · Journal of Clinical Oncology · 2021 · 26 citations

Medicine, Oncology, Pharmacology +17

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Maen Hussein, Marina Maglakelidze, Donald Richards et al. · Cancer Management and Research · 2021 · 23 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

Joshua Tobias, Marina Maglakelidze, Zoran Andrić et al. · Clinical Cancer Research · 2024 · 23 citations · Full text

Medicine, Immunology, Oncology +17

Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection

Philippe Aftimos, Patrick Neven, Mark D. Pegram et al. · Cancer Research · 2021 · 17 citations

Medicine, Oncology, Pharmacology +17